This filing is part of the company’s quarterly result. Read the full results article, with every figure explained →
Standalone results for quarter ended 30 September 2026 approved; review raised no concerns
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 2.1 pts less than Nifty Microcap 250 and 1.2 pts less than its Specialty Chemicals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Standalone unaudited results for the quarter and half year ended 30 September 2026 were approved by the Board; year-on-year revenue and profit figures are not readable in the supplied text. At 30 September 2026, standalone equity was Rs 1,199.94 lakh and cash was Rs 11.30 lakh, with no borrowings shown. Vora and Associates reported nothing indicating a significant error.
The review supports confidence in the accounts, but unclear quarterly comparisons prevent a view on profit direction or likely price impact.
| Q2 FY27 | Q2 FY26 | Change | |
|---|---|---|---|
| Revenue | ₹5.15 Cr | ₹2.81 Cr | +83.2% |
| Operating profit | ₹0.06 Cr | −₹0.02 Cr | turned positive |
| Profit after tax | ₹0.13 Cr | ₹0.09 Cr | +35.5% |
| EBITDA margin | 1.3% | -0.7% | +2.0 pp |
From the company's XBRL filing, not from the text above. Operating profit = profit before tax − exceptional items − other income. EBITDA = profit before tax + finance costs + depreciation − other income.